Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Migraine pills may calm your bladder too – new study

NCT ID NCT06212661

Knowledge-focused Sponsor: The Cleveland Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study from the Cleveland Clinic is looking at whether certain migraine medications (CGRP inhibitors) can also improve bladder symptoms like urgency, frequency, and pain. About 200 women with hard-to-treat migraines and bladder issues will be followed for 3 months. Their symptoms will be compared to those getting Botox injections for migraines, to see if the CGRP drugs offer extra bladder benefits.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CGRP inhibitors (gepants and monoclonal antibodies) and onabotulinumtoxinA (Botox) injections
What this could lead to
If successful, this could show that migraine medications also help bladder symptoms, pointing toward new treatment options for overactive bladder or bladder pain.
What could go wrong
This is an observational study, not a treatment trial, so it cannot prove cause and effect. Results may be small or not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Female patients age 18 years or over, presenting to the neurology outpatient clinics for treatment of refractory migraine with either CGRP inhibitors or Botulinum toxin extracranial muscle injections, and with at least 1 urinary storage-phase symptom in the past month.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female Patients \> 18 years * Refractory migraine, planned treatment with either: * CGRP inhibitors, including: * CGRP small molecule receptor antagonists ("gepants"): Ubrogepant, Rimegepant, Atogepant. * CGRP monoclonal antibodies: Eptinezumab, Fremanezumab, Galcanezumab. * CGRP receptor monoclonal antibodies: Erenumab. * BoNTA extracranial muscle injections * Any of the following symptoms during the last month: * Urinating too often (frequency). * Having a sudden urge to urinate that's difficult to hold back (urgency). * Having a sudden urge to urinate and urine leaking before you make it to the toilet (urge incontinence). Exclusion Criteria: * Age \< 18 years * CGRP treatment within the last 12 months or BoNTA (head / bladder) last 6 months. * Patient (or medical decision-maker) unable to provide informed consent or unable to answer questionnaire. * Unable to urinate, eg: post cystectomy, indwelling catheter, on intermittent self catheterization, ESRD w/ anuria. * Prior bladder BoNTA in last 12 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bladder pain syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

interstitial cystitis migraine disorder overactive bladder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bladder pain syndrome Interstitial cystitis Migraine Migraine disorders Overactive bladder Overactive bladder syndrome Overactive detrusor

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cleveland Clinic, Main Campus

    Cleveland, Ohio, 44195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.